Fresh analysis suggests that patients who stop using popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a leading health publication points out that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using such medications should be aware of the potential of fast rebound weight gain when the therapy ends," stated expert Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment weight within about 18 months.
Comparing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of participants, compared the effects of the injectable medications with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise generally see a slower weight regain—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists suggest the mode of action of the injections accounts for the accelerated regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians contend that, considering the high risk of relapse, the therapy is often long-term.
This opinion is supported by pharmaceutical companies, who state that the results "emphasize the long-term nature of excess weight," akin to managing diseases like high blood pressure.
User Experiences
Users who have stopped the jabs describe a sudden resurgence of cravings.
"It was like a trigger activating and you become ravenous," said an individual.
This difficulty is exacerbated if patients have not established sustainable dietary or behavioural changes during treatment.
Significant Use
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a magic cure and long-term success hinges on integrated behavioural support.
